- Home
- QUMS vs CNTB Comparison
QUMS vs CNTB Comparison
Compare QUMS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$2.00
Company Overview
Basic Information| Metric | QUMS | CNTB |
|---|---|---|
| Founded | 2024 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.8M | 135.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | QUMS | CNTB |
|---|---|---|
| Price | $10.23 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 103.8K | ★ 235.4K |
| Earning Date | 01-01-0001 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.94 | $1.23 |
| 52 Week High | $10.24 | $3.82 |
Technical Indicators
Market Signals| Indicator | QUMS | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 73.57 | 37.79 |
| Support Level | $10.14 | $1.46 |
| Resistance Level | N/A | $2.05 |
| Average True Range (ATR) | 0.01 | 0.19 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 87.50 | 12.17 |
Price Performance
Historical Comparison QUMS
CNTB
About QUMS Quantumsphere Acquisition Corp. Ordinary Shares
Quantumsphere Acquisition Corp is a newly organized blank check company.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.